XBiotech (XBIT) said Thursday that France's National Agency for the Safety of Medicines and Health Products approved the launch of a clinical trial for its...
XBiotech (XBIT) said Wednesday it has signed an agreement to manufacture clinical products, including the Bermekimab antibody drug, for Johnson & Johnson's...
XBiotech (XBIT) said Monday the US FDA has approved its investigational new drug application for Natrunix, allowing the company to start the clinical...
XBiotech (XBIT) said Thursday it plans to start a clinical study to test the safety and efficacy of its new True Human antibody therapy to reduce brain...
| Address | 5217 Winnebago Lane Austin, Texas 78744 |
| Phone | +1.512.386.2900 |
| Number of Employees | 53 |
| Recent SEC Filing | 06/16/2022 SC 13G |
| Chairman, President & Chief Executive Officer | John Simard |
| Vice President-Clinical Operations | Ashley Otero |
| Secretary, VP-Finance & Human Resources | Queena Han |
| Chief Scientific Officer | Sushma Shivaswamy |
| Price Open | $6.28 |
| Previous Close | $6.26 |
| 52 Week Range | $5.09 - 18.46 |
| Market Capitalization | $178.4 M |
| Shares Outstanding | 30.4 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/08/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.67 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | -144.13% |
| Return on Equity | -6.99% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
